India rejects Novartis cancer drug patent

Indian protesters lift a balloon shaped like a medicine capsule during a demonstration against Swiss drug manufacturer Novartis, outside their offices in Mumbai on December 21, 2012.

The Supreme Court in India has rejected an attempt by the Swiss drug maker Novartis to patent an update to a cancer treatment called Gleevec -- spelled Glivec in some markets. The decision is expected to have a big impact on pharmaceutical companies and health organizations far outside the borders of India.

The BBC's Rahul Tandon joins Marketplace Morning Report host Jeremy Hobson to discuss the global pharmaceutical market and the new patent ruling.

Comments

I agree to American Public Media's Terms and Conditions.
With Generous Support From...